These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
835 related articles for article (PubMed ID: 31450787)
1. Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus. Chyuan IT; Tzeng HT; Chen JY Cells; 2019 Aug; 8(9):. PubMed ID: 31450787 [TBL] [Abstract][Full Text] [Related]
2. Abnormalities of the type I interferon signaling pathway in lupus autoimmunity. Gallucci S; Meka S; Gamero AM Cytokine; 2021 Oct; 146():155633. PubMed ID: 34340046 [TBL] [Abstract][Full Text] [Related]
3. Targeting interferons and their pathways in systemic lupus erythematosus. Chasset F; Arnaud L Autoimmun Rev; 2018 Jan; 17(1):44-52. PubMed ID: 29108825 [TBL] [Abstract][Full Text] [Related]
4. High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Oke V; Gunnarsson I; Dorschner J; Eketjäll S; Zickert A; Niewold TB; Svenungsson E Arthritis Res Ther; 2019 Apr; 21(1):107. PubMed ID: 31036046 [TBL] [Abstract][Full Text] [Related]
5. Type 1 interferons: A target for immune-mediated inflammatory diseases (IMIDs). Mathian A; Felten R; Alarcon-Riquelme ME; Psarras A; Mertz P; Chasset F; Vital EM; Arnaud L Joint Bone Spine; 2024 Mar; 91(2):105627. PubMed ID: 37640261 [TBL] [Abstract][Full Text] [Related]
6. Coordination of retrotransposons and type I interferon with distinct interferon pathways in dermatomyositis, systemic lupus erythematosus and autoimmune blistering disease. Kuriyama Y; Shimizu A; Kanai S; Oikawa D; Motegi SI; Tokunaga F; Ishikawa O Sci Rep; 2021 Nov; 11(1):23146. PubMed ID: 34848794 [TBL] [Abstract][Full Text] [Related]
7. Interferons in Systemic Lupus Erythematosus. Sirobhushanam S; Lazar S; Kahlenberg JM Rheum Dis Clin North Am; 2021 Aug; 47(3):297-315. PubMed ID: 34215365 [TBL] [Abstract][Full Text] [Related]
8. Role of interferons in SLE. Bengtsson AA; Rönnblom L Best Pract Res Clin Rheumatol; 2017 Jun; 31(3):415-428. PubMed ID: 29224681 [TBL] [Abstract][Full Text] [Related]
9. Type I interferon signature in systemic lupus erythematosus. Bezalel S; Guri KM; Elbirt D; Asher I; Sthoeger ZM Isr Med Assoc J; 2014 Apr; 16(4):246-9. PubMed ID: 24834763 [TBL] [Abstract][Full Text] [Related]
10. Uncoupling interferons and the interferon signature explains clinical and transcriptional subsets in SLE. Gómez-Bañuelos E; Goldman DW; Andrade V; Darrah E; Petri M; Andrade F Cell Rep Med; 2024 May; 5(5):101569. PubMed ID: 38744279 [TBL] [Abstract][Full Text] [Related]
11. Differential Regulation of Type I and Type III Interferon Signaling. Stanifer ML; Pervolaraki K; Boulant S Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901970 [TBL] [Abstract][Full Text] [Related]
12. Type I Interferons in Systemic Lupus Erythematosus: A Journey from Bench to Bedside. Sim TM; Ong SJ; Mak A; Tay SH Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269647 [TBL] [Abstract][Full Text] [Related]
13. Interferons and systemic lupus erythematosus: Pathogenesis, clinical features, and treatments in interferon-driven disease. Tanaka Y; Kusuda M; Yamaguchi Y Mod Rheumatol; 2023 Aug; 33(5):857-867. PubMed ID: 36440704 [TBL] [Abstract][Full Text] [Related]
14. Type I interferon pathway in pediatric systemic lupus erythematosus. Zhou Y; Song HM World J Pediatr; 2024 Jul; 20(7):653-668. PubMed ID: 38914753 [TBL] [Abstract][Full Text] [Related]
15. Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned. Jones SA; Morand EF Drugs; 2024 Jun; 84(6):625-635. PubMed ID: 38807010 [TBL] [Abstract][Full Text] [Related]
16. The important roles of type I interferon and interferon-inducible genes in systemic lupus erythematosus. Luo S; Wang Y; Zhao M; Lu Q Int Immunopharmacol; 2016 Nov; 40():542-549. PubMed ID: 27769023 [TBL] [Abstract][Full Text] [Related]
17. [Pharmacological actions of anifrolumab (Saphnelo Ueha T; Kusuda M; Shibata S; Hirata M; Ozaki N Nihon Yakurigaku Zasshi; 2022; 157(4):271-279. PubMed ID: 35781459 [TBL] [Abstract][Full Text] [Related]
18. Type I interferon as a target of treatment in SLE. Lee PY; Reeves WH Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):323-30. PubMed ID: 17214578 [TBL] [Abstract][Full Text] [Related]
19. Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupus. Goel RR; Wang X; O'Neil LJ; Nakabo S; Hasneen K; Gupta S; Wigerblad G; Blanco LP; Kopp JB; Morasso MI; Kotenko SV; Yu ZX; Carmona-Rivera C; Kaplan MJ Proc Natl Acad Sci U S A; 2020 Mar; 117(10):5409-5419. PubMed ID: 32094169 [TBL] [Abstract][Full Text] [Related]
20. Cause and consequences of the activated type I interferon system in SLE. Eloranta ML; Rönnblom L J Mol Med (Berl); 2016 Oct; 94(10):1103-1110. PubMed ID: 27094810 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]